Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Sr. Manager, Pharma and Biotech Segment
Connect with Nicki Catchpole on LinkedIn
Follow Nicki Catchpole on Twitter
About the author:
As a professional with over 14 years of experience in strategy development and partnership management across a variety of industries, Nicki’s latest role as a Senior Manager, Segment Marketing at Elsevier applies her skills to the area of drug discovery and development in the Pharma and Biotech industry.
In this capacity she is focused on understanding biopharmaceutical R&D challenges and turning them into opportunity to further Elsevier’s ability to serve industry executives and the professionals who innovate in the drug discovery and development space. Prior to joining Elsevier, Nicki held senior alliance and strategy roles in the Legal, Tax & Accounting, Life Sciences and Cyber Security industries.
Nicki resides in New York City and holds a BA in English Literature and Mandarin Chinese from Carleton College in Northfield, MN.
Posts by Nicki Catchpole
Posted on January 26th, 2019 in Pharma R&D
The U.S. government shutdown dragged on past the one-month mark, creating financial panic for many government workers and resulting in a ripple of negative affects across the country. (more…)
Posted on January 23rd, 2019 in Pharma R&D
There has always been a special relationship between the United States and the United Kingdom that gives the two nations a unique connection. Unfortunately, lately, the two have also shared quite a bit of upheaval and uncertainty in their respective governments.(more…)
Posted on January 15th, 2019 in Pharma R&D
2019 marks the 37th year of the J.P. Morgan Healthcare Conference, which has come to be one of the premiere annual events for companies involved in all aspects of the industry, from biotech start-ups to large healthcare service providers. (more…)
Posted on December 12th, 2018 in Pharma R&D
Innovation used to be almost solely accredited to Big Pharma, but many of the more established businesses in the industry are finding that their rate of discovery is slowing as they try to find answers to some the industry’s biggest problems, such as antibiotic resistance. (more…)